• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

1,658
107
73
69
69

COUNTRY

68
21
17
11
10

CATEGORIES

  • 576
  • 122
  • 558
  • 80
  • 530
  • 43
  • 507
  • 17
  • 19
  • 25

PRICE

813
1,113
1,311
2,779

PUBLISHED

167
274
672
2,779

PRODUCT TYPE

2,204
495
68
7
2
1
1
1

Oncology

The American Cancer Society forecasts that 1,638,910 new cancer cases will occur in the United States in 2012. As cancer rates worldwide are increasing, the oncological sector of the pharmaceutical industry is growing fast and it will continue to provide business opportunities in the next years. However, cancer trials are some of the most complex, time consuming and expensive across all therapeutic areas. What are the new paths to success in this lucrative but challenging market?

Find out the answer in the reports, books, and subscriptions listed under Research and Markets’ Oncology category. Our top-quality publications from industry experts cover every aspect of cancer drug therapy, with a focus on: Lung Cancer, Breast Cancer, Prostate Cancer, Leukaemia, Lymphoma, Ovarian Cancer, Colon Cancer, Cervical Cancer, Brain Cancer and Bladder Cancer. So read on for the latest clinical trials, pipeline reviews, industry news, and commercial opportunities.

Key players featured in our publications include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Wyeth, and many more. Show Less
Read more

PRODUCT TITLE
Triple Analysis: Breast Cancer, Melanoma and Protein Kinase Inhibitors Triple Analysis: Breast Cancer, Melanoma and Protein Kinase Inhibitors - Product Thumbnail Image

Triple Analysis: Breast Cancer, Melanoma and Protein Kinase Inhibitors

This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Melanoma and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual...

June 2013
FROM
Triple Analysis: Breast Cancer, Melanoma and Pancreatic Cancer Triple Analysis: Breast Cancer, Melanoma and Pancreatic Cancer - Product Thumbnail Image

Triple Analysis: Breast Cancer, Melanoma and Pancreatic Cancer

This triple analysis focuses on cancer drug development strategies in Breast Cancer, Melanoma and Pancreatic Cancer. Each of these three individual parts is evaluated according to standardized criteria...

June 2013
FROM
Triple Analysis: Breast Cancer, Melanoma and Prostate Cancer Triple Analysis: Breast Cancer, Melanoma and Prostate Cancer - Product Thumbnail Image

Triple Analysis: Breast Cancer, Melanoma and Prostate Cancer

This triple analysis focuses on cancer drug development strategies in Breast Cancer, Melanoma and Prostate Cancer. Each of these three individual parts is evaluated according to standardized criteria...

June 2013
FROM
Triple Analysis: Breast Cancer, Melanoma and Apoptosis Triple Analysis: Breast Cancer, Melanoma and Apoptosis - Product Thumbnail Image

Triple Analysis: Breast Cancer, Melanoma and Apoptosis

This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Melanoma and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated...

June 2013
FROM
Triple Analysis: Breast Cancer, Lymphoma and Melanoma Triple Analysis: Breast Cancer, Lymphoma and Melanoma - Product Thumbnail Image

Triple Analysis: Breast Cancer, Lymphoma and Melanoma

This triple analysis focuses on cancer drug development strategies in Breast Cancer, Lymphoma and Melanoma. Each of these three individual parts is evaluated according to standardized criteria in a...

June 2013
FROM
Triple Analysis: Breast Cancer, Lung Cancer and Melanoma Triple Analysis: Breast Cancer, Lung Cancer and Melanoma - Product Thumbnail Image

Triple Analysis: Breast Cancer, Lung Cancer and Melanoma

This triple analysis focuses on cancer drug development strategies in Breast Cancer, Lung Cancer and Melanoma. Each of these three individual parts is evaluated according to standardized criteria in...

June 2013
FROM
Triple Analysis: Breast Cancer, Leukemia and Melanoma Triple Analysis: Breast Cancer, Leukemia and Melanoma - Product Thumbnail Image

Triple Analysis: Breast Cancer, Leukemia and Melanoma

This triple analysis focuses on cancer drug development strategies in Breast Cancer, Leukemia and Melanoma. Each of these three individual parts is evaluated according to standardized criteria in a...

June 2013
FROM
Triple Analysis: Breast Cancer, Colorectal Cancer and Melanoma Triple Analysis: Breast Cancer, Colorectal Cancer and Melanoma - Product Thumbnail Image

Triple Analysis: Breast Cancer, Colorectal Cancer and Melanoma

This triple analysis focuses on cancer drug development strategies in Breast Cancer, Colorectal Cancer and Melanoma. Each of these three individual parts is evaluated according to standardized criteria...

June 2013
FROM
Melanoma Drug Development Analysis: From First-in-Class to Best-in-Class? Melanoma Drug Development Analysis: From First-in-Class to Best-in-Class? - Product Thumbnail Image

Melanoma Drug Development Analysis: From First-in-Class to Best-in-Class?

This report gives you a new and unique way of stratifying and analyzing the global melanoma pipeline and presents actionable analysis which allows you to discover: - Where the competition is; Which...

June 2013
FROM

KOL Insight: Prostate Cancer: Competition Intensifies in Race to the Top

The Prostate Cancer market has seen a number of progressive changes in recent years The launches of Johnson & Johnson's Zytiga (abiraterone acetate) and Medivation/Astellas's Xtandi (enzalutamide) has...

June 2013
FROM
Consensus Outlook: Prostate Cancer- Competition intensifies in race to the top Consensus Outlook: Prostate Cancer- Competition intensifies in race to the top - Product Thumbnail Image

Consensus Outlook: Prostate Cancer- Competition intensifies in race to the top

Charting the Future Prostate Cancer Market Landscape The prostate cancer market has experienced substantial changes in the last five years with patent expiries of key compounds and approvals of new...

June 2013
FROM

PharmaPoint: Chronic Myeloid Leukemia (CML) - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Chronic Myeloid Leukemia (CML) - Global Drug Forecast and Market Analysis to 2022 Summary Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized...

May 2013
FROM

Asia-Pacific Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Forecast to 2017

The radiopharmaceuticals market in the Asia-Pacific region was valued at $500 8 million in 2012; it is poised to reach $824 9million in 2017 at a CAGR of 10 5% The market is broadly classified into...

May 2013
FROM

Malignant Glioma - Pipeline Review, H1 2013

Malignant Glioma – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Malignant Glioma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...

May 2013
FROM

Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2013

Recurrent Glioblastoma Multiforme (GBM) – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2013', provides an overview of the...

May 2013
FROM

Sezary Syndrome - Pipeline Review, H1 2013

Sezary Syndrome – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Sezary Syndrome - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...

May 2013
FROM

Gynecological Cancer - Pipeline Review, H1 2013

Gynecological Cancer – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Gynecological Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This...

May 2013
FROM

Cataract - Pipeline Review, H1 2013

Cataract – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Cataract - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

May 2013
FROM

Francisella Tularensis Infections - Pipeline Review, H1 2013

Francisella Tularensis Infections – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Francisella Tularensis Infections - Pipeline Review, H1 2013', provides an overview of the indication’s...

May 2013
FROM

Genital Warts (Condylomata Acuminata) - Pipeline Review, H1 2013

Genital Warts (Condylomata Acuminata) – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Genital Warts (Condylomata Acuminata) - Pipeline Review, H1 2013', provides an overview of the indication’s...

May 2013
FROM
Loading Indicator

Our Clients

Our clients' logos